Caenorhabditis elegans for preclinical drug discovery

Current Science

Volumn 99, Issue 12, 2010, Pages 1669-1680

  Arya, Upasna ^a   Das, Chinmaya Kumar ^a   Subramaniam, Jamuna R ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY KANPUR   (India)

Author keywords

Caenorhabditis elegans; Drug discovery; Lifespan; Neurodegenerative disease

Indexed keywords

CAENORHABDITIS ELEGANS;

EID: 78650992401     PISSN: 00113891     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Brenner, S., The genetics of Caenorhabditis elegans. Genetics, 1974, 77, 71-94.
2. Chalfie, M., Tu, Y., Euskirchen, G., Ward, W. W. and Prasher, D. C., Green fluorescent protein as a marker for gene expression. Science, 1994, 263, 802-805.
3. Kaletta, T. and Hengartner, M. O., Finding function in novel targets: C. elegans as a model organism. Nature Rev. Drug Discov., 2006. 5(5), 387-398.
4. Artal-Sanz, M., de Long, L. and Tavernarakis, N. Caenorhabditis elegans: a versatile platform for drug discovery. Biotechnol. J., 2006, 1, 1405-1418.
5. Hertweck, M. A. and Baumister, R., Automated assays to study longevity in C. elegans. Mech. Ageing Develop., 2005, 126, 139-145.
6. Benedetti, M. et al., Compounds that confer thermal stress resistance and extended lifespan. Exp. Gerontol., 2008, 43, 882-891.
7. Boyd, W. A., McBride, S. J. and Freedman, J. H., Effects of genetic mutations and chemical exposures on Caenorhabditis elegans feeding: evaluation of a novel, high-throughput screening assay. PLoS One, 2007, 2(12): e1259.
8. Boyd, W. A., Smith, M. V., Kissling, G. E. and Freedman, J. H., Medium- and high-throughput screening of neurotoxicants using C. elegans. Neurotoxicol. Teratol., 2010, 32(1), 68-73.
9. Chakrapani, B. P., Kumar, S. and Subramaniam, J. R., Development and evaluation of an in vivo assay in Caenorhabditis elegans for screening of compounds for their effect on cytochrome P450 expression. J. Biosci., 2008, 33(2), 269-277.
10. Schafer, W. R., Addiction research in a simple animal model: the nematode Caenorhabditis elegans. Neuropharmacology (Suppl 1), 2004, 47, 123-131.
11. Hengartner, M. O. and Horvitz, H. R., Programmed cell death in Caenorhabditis elegans. Curr. Opin. Genet. Dev., 1994, 4(4), 581-586.
12. Hengartner, M. O. and Horvitz, H. R., The ins and outs of programmed cell death during C. elegans development. Philos. Trans. R. Soc. London Ser. B, 1994, 345(1313), 243-246.
13. Thompson, C. B., Apoptosis in the pathogenesis and treatment of disease. Science, 1995, 267(5203), 1456-1462.
14. Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E. and Mello, C. C., Potent and specific genetic interference by doublestranded RNA in Caenorhabditis elegans. Nature, 1998, 391(6669), 806-811.
15. Olsen, P. H. and Ambros, V., The lin-4 regulatory RNA controls developmental timing in Caenorhabditis elegans by blocking LIN-14 protein synthesis after the initiation of translation. Dev. Biol., 1999, 216(2), 671-680.
16. Reinhart, B. J. et al., The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature, 2000, 403(6772), 901-906.
17. Simon, D. J. et al., The microRNA miR-1 regulates a MEF-2-dependent retrograde signal at neuromuscular junctions. Cell, 2008, 133(5), 903-915.
18. Poy, M. N. et al., A pancreatic islet-specific microRNA regulates insulin secretion. Nature, 2004, 432(7014), 226-230.
19. Johnson, R., Zuccato, C., Belyaev, N. D., Guest, D. J., Cattaneo, E. and Buckley, N. J., A microRNA-based gene dysregulation pathway in Huntington's disease. Neurobiol. Dis., 2008, 29(3), 438-445.
20. Alper, S., Laws, R., Lackford, B., Boyd, W. A., Dunlap, P., Freedman, J. H. and Schwartz, D. A., Identification of innate immunity genes and pathways using a comparative genomics approach. Proc. Natl. Acad. Sci. USA, 2008, 105(19), 7016- 7021.
21. Powell, J. R. and Ausubel, F. M., Models of Caenorhabditis elegans infection by bacterial and fungal pathogens. Meth. Mol. Biol., 2008, 415, 403-427.
22. Adonizio, A., Leal Jr, S. M., Ausubel, F. M. and Mathee, K., Attenuation of Pseudomonas aeruginosa virulence by medicinal plants in a Caenorhabditis elegans model system. J. Med. Microbiol., 2008, 57, 809-813.
23. Moy, T. I., Ball, A. R., Anklesaria, Z., Casadei, G., Lewis, K. and Ausubel, F. M., Identification of novel antimicrobials using a liveanimal infection model. Proc. Natl. Acad. Sci. USA, 2006, 103(27), 10414-10419.
24. Breger, J., Fuchs, B. B., Aperis, G., Moy, T. I., Ausubel, F. M. and Mylonakis, E., Antifungal chemical compounds identified using a C. elegans pathogenicity assay. PLoS Pathogens, 2007, 3(2), e18.
25. Gaud, A., Simon, J. M., Witzel, T., Carre-Pierrat, M., Wermuth, C. G. and Ségalat, L., Prednisone reduces muscle degeneration in dystrophin-deficient Caenorhabditis elegans. Neuromuscul. Disord., 2004, 14(6), 365-370.
26. Carre-Pierrat, M. et al., Blocking of striated muscle degeneration by serotonin in C. elegans. J. Muscle Res. Cell Motil., 2006, 27 (3-4), 253-258.
27. Giacomotto, J. et al., Evaluation of the therapeutic potential of carbonic anhydrase inhibitors in two animal models of dystrophin deficient muscular dystrophy. Hum. Mol. Genet., 2009, 18(21), 4089-4101.
28. Ashrafi, K., Chang, F. Y., Watts, J. L., Fraser, A. G., Kamath, R. S., Ahringer, J. and Ruvkun, G. Genome-wide RNAi analysis of Caenorhabditis elegans fat regulatory genes. Nature, 2003, 421(6920), 268-272.
29. Mukhopadhyay, A., Deplancke, B., Walhout, A. J. and Tissenbaum, H. A., C. elegans tubby regulates lifespan and fat storage by two independent mechanisms. Cell Metab., 2005, 2(1), 35-42.
30. Ashrafi, K., Obesity and the regulation of fat metabolism. Worm-Book (ed. The C. elegans Research Community), 2007, doi/10.1895/wormbook.1.130; http://www.wormbook.org
31. Ross, C. A. and Poirier, M. A., Protein aggregation and neurodegenerative disease. Nature Med., 2004, 10, s10-s17.
32. Link, C. D., Expression of human-amyloid peptide in transgenic Caenorhabditis elegans. Proc. Natl. Acad. Sci. USA, 1995, 92, 9368-9372.
33. Link, C. D., Transgenic invertebrate models of age-associated neurodegenerative diseases. Mech. Ageing Dev., 2001, 122, 1639-1649.
34. Link, C. D., Invertebrate models of Alzheimer's disease. Genes, Brain Behav., 2005, 4, 147-156.
35. Riddle, D. L., Meyer, B. J. and Priess, J. R. (eds) C. elegans II, Cold Spring Harbor Laboratory Press, 1997, p. 612.
36. Drake, J., Link, C. D., Butterfield, D. A., Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid-peptide (1-42) in a transgenic Caenorhabditis elegans model. Neurobiol. Aging, 2003, 24, 415-420.
37. Wu, Y. et al., Amyloid-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and Ginkgolides in transgenic Caenorhabditis elegans. J. Neurosci., 2006, 26(50), 13102-13113.
38. Morley, J. F., Brignull, H. R., Weyers, J. J. and Morimoto, R. I., The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proc. Natl. Acad. Sci. USA, 2002, 99(16), 10417-10422.
39. Faber, P. W., Alter, J. R., Macdonald, M. E. and Hart, A. C., Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron. Proc. Natl. Acad. Sci. USA, 1999, 96, 179-184.
40. Parker, J. A., Holbert, S., Lambert, E., Abderrahmane, S. and Neri, C., Genetic and pharmacological suppression of polyglutamine-dependent neuronal dysfunction in Caenorhabditis elegans. J. Mol. Neurosci., 2004, 23, 61-67.
41. Parker, J. A., Connolly, J. B., Wellington, C., Hayden, M., Dausset, J. and Neri, C., Expanded polyglutamines in Caenorhabditis elegans cause axonal abnormalities and severe dysfunction of PLM mechanosensory neurons without cell death. Proc. Natl. Acad. Sci. USA, 2001, 98(23), 13318-13323.
42. Lakso, M. et al., Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human a-synuclein. J. Neurochem., 2003, 86, 165-172.
43. Locke, C. J., Fox, S. A., Caldwell, G. A. and Caldwell, K. A., Acetaminophen attenuates dopamine neuron degeneration in animal models of Parkinson's disease. Neurosci. Lett., 2008, 439, 129-133.
44. Hamamichi, S., Rivas, R. N., Knight, A. L., Cao, S., Caldwell, K. A. and Caldwell, G. A., Hypothesis-based RNAi screening identifies neuroprotective genes in a Parkinson's disease model. Proc. Natl. Acad. Sci. USA, 2008, 105(2), 728-733.
45. Marvanova, M. and Nichols, C. D., Identification of neuroprotective compounds of Caenorhabditis elegans dopaminergic neurons against 6-OHDA. J. Mol. Neurosci., 2006, 31, 127-138.
46. Braungart, E., Gerlachb, M., Riedererb, P., Baumeister, R. and Hoenerd, M. C., Caenorhabditis elegans MPP+ model of Parkinson's disease for high-throughput drug screenings. Neurodegener. Dis., 2004, 1, 175-183.
47. Wang, J., Farr, G. W., Hall, D. H., Li, F., Furtak, K., Dreier, L. and Horwich, A. L., An ALS-linked mutant SOD1 produces a locomotor defect associated with aggregation and synaptic dysfunction when expressed in neurons of Caenorhabditis elegans. PLoS Genet, 2009, 5(1), e1000350.
48. Ma, C., Animal models of disease. Mod. Drug Discov., 2004, 7(6), 30-36.
49. Zepeda, A. G. et al., Soy isoflavone glycitein protects against beta amyloid-induced toxicity and oxidative stress in transgenic Caenorhabditis elegans. BMC Neurosci., 2005, 6, 54.
50. Arya, U., Dwivedi, H. and Subramaniam, J. R., Reserpine ameliorates Abeta toxicity in the Alzheimer's disease model in C. elegans. Exp. Gerontol., 2009. 44(6-7), pp. 462-466.
51. Strayer, A., Wu, Z., Christen, Y., Link, C. D. and Luo, Y., Expression of the small heat-shock protein Hsp-16-2 in Caenorhabditis elegans is suppressed by Ginkgo biloba extract EGb 761. FASEB J., 2003, 17(15), 2305-2307.
52. Bates, E. A., Victor, M., Jones, A. K., Shi, Y. and Hart, A. C., Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity. J. Neurosci., 2006, 26(10), 2830-2838.
53. Voisine, C., Varma, H., Walker, N., Bates, E. A., Stockwell, B. R. and Hart, A. C., Identification of potential therapeutic drugs for Huntington's disease using Caenorhabditis elegans. PLoS One, 2007, 2(6), 504.
54. Parker, J. A., Arango, M., Abderrahmane, S., Lambert, E., Tourette, C., Catoire, H. and Neri, C., Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nature Genet., 2005, 37(4), 349-350.
55. Mojsilovic-Petrovic, J. et al., FOXO3a is broadly neuroprotective in vitro and in vivo against insults implicated in motor neuron diseases. J. Neurosci., 2009, 29(25), 8236-8247.
56. Menzel, R., Bogaert, T. and Achazi, R., A systematic gene expression screen of Caenorhabditis elegans cytochrome P450 genes reveals CYP35 as strongly xenobiotic inducible. Arch. Biochem. Biophys., 2001, 395(2), 158-168.
57. Friedman, D. B. and Johnson, T. E., A mutation in the age-1 gene in Caenorhabditis elegans lengthens life and reduces hermaphrodite fertility. Genetics, 1988, 118(1), 75-86.
58. Kenyon, C., Chang, J., Gensch, E., Rudner, A. and Tabtiang, R., A C. elegans mutant that lives twice as long as wild type. Nature, 1993, 366(6454), 461-464.
59. Wolkow, C. A., Kimura, K. D., Lee, M. S. and Ruvkun, G., Regulation of C. elegans life-span by insulinlike signaling in the nervous system. Science, 2000, 290(5489), 147-150.
60. Wood, J. G., Rogina, B., Lavu, S., Howitz, K., Helfand, S. L., Tatar, M. and Sinclair, D., Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature, 2004, 430(7000), 686-689.
61. Lakowski, B. and Hekimi, S., Determination of life-span in Caenorhabditis elegans by four clock genes. Science, 1996, 272(5264), 1010-1013.
62. Arantes-Oliveira, N., Berman, J. R. and Kenyon, C., Healthy animals with extreme longevity. Science, 2003, 302(5645), 611.
63. McColl, G., Killilea, D. W., Hubbard, A. E., Vantipalli, M. C., Melov, S. and Lithgow, G. J., Pharmacogenetic analysis of lithium-induced delayed aging in Caenorhabditis elegans. J. Biol. Chem., 2008, 283(1), 350-357.
64. Srivastava, D., Arya, U., SoundaraRajan, T., Dwivedi, H., Kumar, S. and Subramaniam, J. R., Reserpine can confer stress tolerance and lifespan extension in the nematode C. elegans. Biogerontology, 2008, 9(5), 309-316.
65. Pinkston, J. M., Garigan, D., Hansen, M. and Kenyon, C., Mutations that increase the lifespan of C. elegans inhibit tumor growth. Science, 2006, 313(5789), 971-975.
66. Reddy, K. C., Andersen, E. C., Kruglyak, L. and Kim, D. H., A polymorphism in npr-1 is a behavioral determinant of pathogen susceptibility in C. elegans. Science, 2009, 323(5912), 382-384.
67. Garsin, D. A. et al., Long-lived C. elegans daf-2 mutants are resistant to bacterial pathogens. Science, 2003, 300(5627), 1921.
68. Morley, J. F., Brignull, H. R., Weyers, J. J. and Morimoto, R. I., The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proc. Natl. Acad. Sci. USA, 2002, 99(16), 10417-10422.
69. Cohen, E., Bieschke, J., Perciavalle, R. M., Kelly, J. W. and Dillin, A., Opposing activities protect against age-onset proteotoxicity. Science, 2006, 313(5793), 1604-1610.
70. Hsu, A. L., Murphy, C. T. and Kenyon, C., Regulation of aging and age-related disease by DAF-16 and heat-shock factor. Science, 2003, 300(5622), 1142-1145.
71. Evason, K., Huang, C., Yamben, I., Covey, D. F. and Kornfeld, K., Anticonvulsant medications extend worm life-span. Science, 2005, 307(5707), 258-262.
72. Petrascheck, M., Ye, X. and Buck, L. B., An antidepressant that extends lifespan in adult Caenorhabditis elegans. Nature, 2007, 450(7169), 553-556.
73. Baur, J. A. et al., Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 2006, 444(7117), 337-342.
74. Wilson, M. A., Shukitt-Hale, B., Kalt, W., Ingram, D. K., Joseph, J. A. and Wolkow, C. A., Blueberry polyphenols increase lifespan and thermotolerance in Caenorhabditis elegans. Aging Cell, 2006, 5(1), 59-68.
75. Wu, Z., Smith, J. V., Paramasivam, V., Butko, P., Khan, I., Cypser, J. R. and Luo, Y., Ginkgo biloba extract EGb 761 increases stress resistance and extends life span of Caenorhabditis elegans. Cell. Mol. Biol., 2002, 48(6), 725-731.
76. Kamath, R. S. et al., Systematic functional analysis of the Caenorhabditis elegans genome using RNAi. Nature, 2003, 421, 231-237.
77. Kwok, T. C. et al., A small-molecule screen in C. elegans yields a new calcium channel antagonist. Nature, 2006, 441, 91-95.
78. Dempsey, C. M., Gargus, A., Blanco, G. and Sze, J. Y. Serotonin (5HT), fluoxetine, imipramine and dopamine target distinct 5HT receptor signaling to modulate Caenorhabditis elegans egg-laying behaviour. Genetics, 2005, 169(3), 1425-1436.
79. Briese, M. et al., Deletion of smn-1, the Caenorhabditis elegans ortholog of the spinal muscular atrophy gene, results in locomotor dysfunction and reduced lifespan. Hum. Mol. Genet., 2009, 18(1), 97-104.
80. Zhao, J., Matthies, D. S., Botzolakis, E. J., Macdonald, R. L., Blakely, R. D. and Hedera, P., Hereditary spastic paraplegiaassociated mutations in the NIPA1 gene and its Caenorhabditis elegans homolog trigger neural degeneration in vitro and in vivo through a gain-of-function mechanism. J. Neurosci., 2008, 28(51), 13938-13951.
81. Bell, A., Monaghan, P. and Page, A. P., Peptidyl-prolyl cis-trans isomerases (immunophilins) and their roles in parasite biochemistry, host-parasite interaction and antiparasitic drug action. Int. J. Parasitol., 2006, 36(3), 261-276.